131 related articles for article (PubMed ID: 35182042)
1. Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects.
Mathis A; Collins D; Dobo S; Walling DM; Sheridan WP; Taylor R
Clin Pharmacol Drug Dev; 2022 Apr; 11(4):467-474. PubMed ID: 35182042
[TBL] [Abstract][Full Text] [Related]
2. An update on the progress of galidesivir (BCX4430), a broad-spectrum antiviral.
Julander JG; Demarest JF; Taylor R; Gowen BB; Walling DM; Mathis A; Babu YS
Antiviral Res; 2021 Nov; 195():105180. PubMed ID: 34551346
[TBL] [Abstract][Full Text] [Related]
3. An E460D Substitution in the NS5 Protein of Tick-Borne Encephalitis Virus Confers Resistance to the Inhibitor Galidesivir (BCX4430) and Also Attenuates the Virus for Mice.
Eyer L; Nougairède A; Uhlířová M; Driouich JS; Zouharová D; Valdés JJ; Haviernik J; Gould EA; De Clercq E; de Lamballerie X; Ruzek D
J Virol; 2019 Aug; 93(16):. PubMed ID: 31142664
[TBL] [Abstract][Full Text] [Related]
4. A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques.
Lim SY; Osuna CE; Best K; Taylor R; Chen E; Yoon G; Kublin JL; Schalk D; Schultz-Darken N; Capuano S; Safronetz D; Luo M; MacLennan S; Mathis A; Babu YS; Sheridan WP; Perelson AS; Whitney JB
Sci Transl Med; 2020 Jun; 12(547):. PubMed ID: 32522808
[TBL] [Abstract][Full Text] [Related]
5. Activity of Galidesivir in a Hamster Model of SARS-CoV-2.
Taylor R; Bowen R; Demarest JF; DeSpirito M; Hartwig A; Bielefeldt-Ohmann H; Walling DM; Mathis A; Babu YS
Viruses; 2021 Dec; 14(1):. PubMed ID: 35062212
[TBL] [Abstract][Full Text] [Related]
6. Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters.
Westover JB; Mathis A; Taylor R; Wandersee L; Bailey KW; Sefing EJ; Hickerson BT; Jung KH; Sheridan WP; Gowen BB
Antiviral Res; 2018 Aug; 156():38-45. PubMed ID: 29864447
[TBL] [Abstract][Full Text] [Related]
7. Galidesivir Triphosphate Promotes Stalling of Dengue-2 Virus Polymerase Immediately Prior to Incorporation.
Deshpande S; Huo W; Shrestha R; Sparrow K; Wood JM; Evans GB; Harris LD; Kingston RL; Bulloch EMM
ACS Infect Dis; 2023 Aug; 9(8):1658-1673. PubMed ID: 37488090
[TBL] [Abstract][Full Text] [Related]
8. BCX4430 - A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease.
Taylor R; Kotian P; Warren T; Panchal R; Bavari S; Julander J; Dobo S; Rose A; El-Kattan Y; Taubenheim B; Babu Y; Sheridan WP
J Infect Public Health; 2016; 9(3):220-6. PubMed ID: 27095300
[TBL] [Abstract][Full Text] [Related]
9. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.
Warren TK; Wells J; Panchal RG; Stuthman KS; Garza NL; Van Tongeren SA; Dong L; Retterer CJ; Eaton BP; Pegoraro G; Honnold S; Bantia S; Kotian P; Chen X; Taubenheim BR; Welch LS; Minning DM; Babu YS; Sheridan WP; Bavari S
Nature; 2014 Apr; 508(7496):402-5. PubMed ID: 24590073
[TBL] [Abstract][Full Text] [Related]
10. Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects.
Liu X; Xue L; Zhang H; Xu Q; Zhang S; Ma S; Ding X; Liu L; Dong J; Qian L; Xia W; Jiang K; Huang C; Miao L
Clin Drug Investig; 2020 Jun; 40(6):555-566. PubMed ID: 32277364
[TBL] [Abstract][Full Text] [Related]
11. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
[TBL] [Abstract][Full Text] [Related]
12. BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model.
Julander JG; Bantia S; Taubenheim BR; Minning DM; Kotian P; Morrey JD; Smee DF; Sheridan WP; Babu YS
Antimicrob Agents Chemother; 2014 Nov; 58(11):6607-14. PubMed ID: 25155605
[TBL] [Abstract][Full Text] [Related]
13. Two Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Studies To Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza A Virus Monoclonal Antibody, MHAA4549A, in Healthy Volunteers.
Lim JJ; Deng R; Derby MA; Larouche R; Horn P; Anderson M; Maia M; Carrier S; Pelletier I; Burgess T; Kulkarni P; Newton E; Tavel JA
Antimicrob Agents Chemother; 2016 Sep; 60(9):5437-44. PubMed ID: 27381392
[TBL] [Abstract][Full Text] [Related]
14. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety and tolerability of Bencycloquidium bromide, a novel selective muscarinic M1/M3 receptor antagonist, after single and multiple intranasal doses in healthy chinese subjects: an open-label, single-center, first-in-human study.
Sun L; Ding L; Wang Y; Zhou W; Yan Z; Sun W; Zhang H; Ou N; Chen X
Drugs R D; 2012 Mar; 12(1):17-28. PubMed ID: 22339483
[TBL] [Abstract][Full Text] [Related]
16. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.
Chandra KP; Shiwalkar A; Kotecha J; Thakkar P; Srivastava A; Chauthaiwale V; Sharma SK; Cross MR; Dutt C
Clin Drug Investig; 2009; 29(9):559-75. PubMed ID: 19663519
[TBL] [Abstract][Full Text] [Related]
17. Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
Shiozaki T; Ueno T; Nagashima H; Yamahira N; Hiraoka M; Eley T; Bifano M; Bertz RJ
Int J Clin Pharmacol Ther; 2015 Apr; 53(4):292-302. PubMed ID: 25740262
[TBL] [Abstract][Full Text] [Related]
18. First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults.
Mammen MP; Armas D; Hughes FH; Hopkins AM; Fisher CL; Resch PA; Rusalov D; Sullivan SM; Smith LR
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427299
[TBL] [Abstract][Full Text] [Related]
19. Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men.
van Troostenburg AR; Clark EV; Carey WD; Warrington SJ; Kerns WD; Cohn I; Silverman MH; Bar-Yehuda S; Fong KL; Fishman P
Int J Clin Pharmacol Ther; 2004 Oct; 42(10):534-42. PubMed ID: 15516022
[TBL] [Abstract][Full Text] [Related]
20. Safety, Tolerability, and Pharmacokinetics of JNJ-1802, a Pan-serotype Dengue Direct Antiviral Small Molecule, in a Phase 1, Double-Blind, Randomized, Dose-Escalation Study in Healthy Volunteers.
Ackaert O; Vanhoutte F; Verpoorten N; Buelens A; Lachau-Durand S; Lammens L; Hoetelmans R; Van Loock M; Herrera-Taracena G
Clin Infect Dis; 2023 Sep; 77(6):857-865. PubMed ID: 37161721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
